WELTRUZA

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
WELTRUZA
Generic name
OLANZAPINE
Manufacturer
Teva Pharmaceuticals USA, Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
a23e99c7-fb76-46d2-95af-e03d5a4d1f2c
SPL ID
1c998762-8d30-4afd-b0d5-282bcaaefb8d
Version
5
Effective date
2026-10-26
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:20:45
Harmonized routes table
Harmonized routes
SUBCUTANEOUS

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. WELTRUZA is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. WELTRUZA is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 , 8.5 )

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 2 of 2 · 7 matching rows.

warnings and cautions table

<table width="800px" cellpadding="5"> <caption>Table 2: Changes in Fasting Glucose Levels from Adult Olanzapine Monotherapy Studies</caption> <col/> <col/> <col/> <col/> <col/> <col/> <col/> <tbody> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/> <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold"> Up to 12 weeks exposure</content> </td> <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold"> At least 48 weeks exposure</content> </td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Laboratory Analyte </content> </td> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Category Change (at least once) from Baseline</content> </td> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Treatment Arm</content> </td> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">N</content> </td> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Patients</content> </td> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">N</content> </td> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Patients</content> </td> </tr> <tr> <td align="center" rowspan="5" styleCode=" Botrule Toprule Lrule Rrule"> Fasting Glucose</td> </tr> <tr> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Normal to High (&lt;100 mg/dL to &#x2265;126 mg/dL) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Olanzapine</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 543</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2.2% </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 345</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">12.8% </td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Placebo</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 293</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">3.4% </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">NA<sup>a</sup> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">NA<sup>a</sup> </td> </tr> <tr> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Borderline to High (&#x2265;100 mg/dL and &lt;126 mg/dL to &#x2265;126 mg/dL)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Olanzapine</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 178</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">17.4% </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">127 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 26.0%</td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Placebo</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 96</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">11.5% </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">NA<sup>a</sup> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NA<sup>a</sup> </td> </tr> <tr> <td colspan="7"> <sup>a </sup>Not Applicable </td> </tr> </tbody> </table>

warnings and cautions table

<table width="1000px" cellpadding="5"> <caption>Table 3: Changes in Fasting Lipids Values from Adult Olanzapine Monotherapy Studies</caption> <col/> <col/> <col/> <col/> <col/> <col/> <col/> <tbody> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/> <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold"> Up to 12 weeks exposure </content> </td> <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold"> At least 48 weeks exposure</content> </td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Laboratory Analyte </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Category Change (at least once) from Baseline</content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Treatment Arm </content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">N</content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Patients</content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">N</content> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Patients</content> </td> </tr> <tr> <td align="center" rowspan="6" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> Fasting </paragraph> <paragraph>Triglycerides</paragraph> </td> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Increase by &#x2265;50 mg/dL</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Olanzapine </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 745</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 39.6%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 487</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">61.4% </td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Placebo </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">402 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 26.1%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NA<sup>a</sup> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NA<sup>a</sup> </td> </tr> <tr> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Normal to High (&lt;150 mg/dL to &#x2265;200 mg/dL)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Olanzapine</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 457</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">9.2%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">293 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">32.4% </td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Placebo</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 251</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">4.4%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NA<sup>a</sup> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NA<sup>a</sup> </td> </tr> <tr> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Borderline to High (&#x2265;150 mg/dL and &lt;200 mg/dL to &#x2265;200 mg/dL) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Olanzapine</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 135</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 39.3%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 75</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">70.7% </td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Placebo</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 65</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 20.0%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NA<sup>a</sup> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NA<sup>a</sup> </td> </tr> <tr> <td align="center" colspan="4" styleCode=" Botrule Toprule Lrule Rrule"> </td> <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule"> </td> </tr> <tr> <td align="center" rowspan="6" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> Fasting Total </paragraph> <paragraph>Cholesterol</paragraph> </td> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Increase by &#x2265;40 mg/dL </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Olanzapine </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">745 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">21.6% </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 489</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">32.9% </td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Placebo</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 402</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">9.5% </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NA<sup>a</sup> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">NA<sup>a</sup> </td> </tr> <tr> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Normal to High (&lt;200 mg/dL to &#x2265;240 mg/dL) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Olanzapine</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 392</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2.8%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 283</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">14.8% </td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Placebo</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">207 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2.4%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NA<sup>a</sup> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">NA<sup>a</sup> </td> </tr> <tr> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Borderline to High (&#x2265;200 mg/dL and &lt;240 mg/dL to &#x2265;240 mg/dL) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Olanzapine</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">222 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 23.0%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 125</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 55.2%</td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Placebo</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">112</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">12.5%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NA<sup>a</sup> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">NA<sup>a</sup> </td> </tr> <tr> <td align="center" colspan="7" styleCode=" Botrule Toprule Lrule Rrule"> </td> </tr> <tr> <td align="center" rowspan="6" styleCode=" Botrule Toprule Lrule Rrule"> Fasting LDL <paragraph>Cholesterol</paragraph> </td> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Increase by &#x2265;30 mg/dL </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Olanzapine</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 536</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">23.7% </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">483 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">39.8% </td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Placebo</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">304 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14.1%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NA<sup>a</sup> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">NA<sup>a</sup> </td> </tr> <tr> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Normal to High (&lt;100 mg/dL to &#x2265;160 mg/dL)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Olanzapine</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">154 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 0%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 123</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 7.3%</td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Placebo</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 82</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 1.2%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NA<sup>a</sup> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">NA<sup>a</sup> </td> </tr> <tr> <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Borderline to High (&#x2265;100 mg/dL and &lt;160 mg/dL to &#x2265;160 mg/dL) </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Olanzapine</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 302</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 10.6%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 284</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 31.0%</td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Placebo</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 173</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8.1%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NA<sup>a</sup> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> NA<sup>a</sup> </td> </tr> <tr> <td colspan="7" styleCode=" Toprule"> <sup>a </sup>Not Applicable </td> </tr> </tbody> </table>

warnings and cautions table

<table width="800px" cellpadding="5"> <caption>Table 4: Weight Gain with Olanzapine Use in Adults</caption> <col/> <col/> <col/> <col/> <col/> <col/> <tbody> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Amount Gained </content> <content styleCode="bold">kg (lb)</content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">6 Weeks </content> <content styleCode="bold">(N=7465) </content> <content styleCode="bold">(%)</content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">6 Months </content> <content styleCode="bold">(N=4162) </content> <content styleCode="bold">(%)</content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">12 Months </content> <content styleCode="bold">(N=1345) </content> <content styleCode="bold">(%)</content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">24 Months </content> <content styleCode="bold">(N=474) </content> <content styleCode="bold">(%)</content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">36 Months </content> <content styleCode="bold">(N=147) </content> <content styleCode="bold">(%)</content> </paragraph> </td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&#x2264;0</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">26.2</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 24.3</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">20.8 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 23.2</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 17.0</td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0 to &#x2264;5 (0-11 lb)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">57.0</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 36.0</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 26.0</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 23.4</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">25.2 </td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&gt;5 to &#x2264;10 (11-22 lb)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">14.9</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 24.6</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 24.2</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 24.1</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 18.4</td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&gt;10 to &#x2264;15 (22-33 lb)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">1.8</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 10.9</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14.9</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 11.4</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">17.0 </td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&gt;15 to &#x2264;20 (33-44 lb)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.1</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 3.1</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8.6</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 9.3</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 11.6</td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&gt;20 to &#x2264;25 (44-55 lb)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.9 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">3.3 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 5.1</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 4.1</td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">&gt;25 to &#x2264;30 (55-66 lb)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.2 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 1.4</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2.3</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 4.8</td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> &gt;30 (&gt;66 lb)</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 0</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0.1 </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 0.8</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 1.2</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2</td> </tr> </tbody> </table>

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 3 · 9 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Boxed Warning and Warnings and Precautions ( 5.1 )] Post-Injection Delirium/Sedation Syndrome [see Warnings and Precautions ( 5.2 )] Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis [see Warnings and Precautions ( 5.3 )] Neuroleptic Malignant Syndrome (NMS) [see Warnings and Precautions ( 5.4 )] Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) [see Warnings and Precautions ( 5.5 )] Metabolic Changes [see Warnings and Precautions ( 5.6 )] Tardive Dyskinesia [see Warnings and Precautions ( 5.7 )] Orthostatic Hypotension [see Warnings and Precautions ( 5.8 )] Falls [see Warnings and Precautions ( 5.9 )] Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions ( 5.10 )] Dysphagia [see Warnings and Precautions ( 5.11 )] Seizures [see Warnings and Precautions ( 5.12 )] Potential for Cognitive and Motor Impairment [see Warnings and Precautions ( 5.13 )] Body Temperature Regulation [see Warnings and Precautions ( 5.14 )] Anticholinergic (antimuscarinic) Effects [see Warnings and Precautions ( 5.15 )] Hyperprolactinemia [see Warnings and Precautions ( 5.16 )] Most common adverse reactions (≥5% in at least one of the treatment groups and greater than placebo) associated with WELTRUZA treatment: Weight increased, Somnolence, Headache, Constipation, and Injection Site Reactions (induration, pain, erythema, pruritus, swelling). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice. The safety of WELTRUZA for the treatment of schizophrenia in adults is based on adequate and well controlled studies of oral olanzapine in studies of patients with schizophrenia and other indications as well as in one 8-week placebo-controlled trial of WELTRUZA in adult patients with schizophrenia [see Clinical Studies ( 14 )]. The information below for WELTRUZA is derived primarily from a clinical trial database consisting of 849 patients receiving 3971 injections of WELTRUZA in 4 clinical trials. The majority of the safety data in this database is from a single phase 3 randomized, double-blind, placebo-controlled trial with an open-label, long-term safety phase conducted in patients with schizophrenia, with additional data from 3 open-label phase 1 trials, conducted in patients with schizophrenia or schizoaffective disorder. Additionally, data obtained from patients treated with oral olanzapine is also presented below. The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. Reactions listed elsewhere in labeling may not be repeated below. The entire label should be read to gain a complete understanding of the safety profile of WELTRUZA. The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects during usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing healthcare provider with some basis for estimating the relative contribution of drug and nondrug factors to the adverse reaction incidence in the population studied. Adverse Reactions Associated with Discontinuation of Trial in a Short-Term, Placebo-Controlled Period Overall, there was no meaningful difference in the incidence of discontinuation due to adverse reactions between WELTRUZA (5%; 23/500 patients) and placebo (4%; 6/167 patients) in an 8-week period. None of these Adverse Reactions occurred in >1% of patients. Commonly Observed Adverse Reactions in a Short-Term, Placebo-Controlled Trial The systemic safety profile of WELTRUZA was consistent with that of oral olanzapine. As such, injection site reactions (ISRs) are presented separately below, since they are specific to the injectable route of administration. In an 8-week placebo-controlled period, adverse reactions with an incidence of 5% or greater in at least one of the WELTRUZA treatment groups (318 mg, 425 mg, or 531 mg) and greater than placebo were: weight gain, injection site induration, injection site pain, injection site erythema, somnolence, headache, injection site pruritus, injection site swelling, and constipation. Adverse Reactions are presented in Table 5. Specific injection site reactions are presented in Table 6. Adverse Reactions Occurring at an Incidence of 2% or more among WELTRUZA-Treated Patients in a Short-Term, Placebo-Controlled Period of a Clinical Trial Table 5 enumerates the incidence, rounded to the nearest percent, of adverse reactions that occurred in 2% or more of patients treated with WELTRUZA and with incidence greater than placebo who participated in the 8-week, placebo-controlled period. Table 5: Adverse Reactions: Incidence in a Short-Term, Placebo-Controlled Period of a clinical trial occurring in ≥2% of patients in any WELTRUZA Group and Greater than Placebo Percentage of Patients Reporting Adverse Reaction Placebo (N=167) WELTRUZA 318mg (N=163) WELTRUZA 425mg (N=168) WELTRUZA 531mg (N=169) Investigations Weight increased 9% 30% 39% 34% Waist circumference increased 1% 1% 2% 3% Nervous System Disorders Somnolence 2% 10% 6% 8% Headache 7% 6% 8% 4% Gastrointestinal disorders Constipation 4% 2% 5% 5% Dry mouth 1% 2% 3% 4% Dyspepsia 1% 4% 2% 1% Toothache 0% 2% 1% 1% Nausea 2% 2% 1% 1% Metabolism and nutrition disorders Increased appetite 2% 4% 2% 2% Respiratory, thoracic and mediastinal disorders Cough 0% 1% 1% 3% General disorders and administration site conditions Injection site reaction* 8% 26% 29% 31% Fatigue 1% 2% 2% 1% Musculoskeletal and connective tissue disorders Schizophrenia 0% 2% 0% 2% Anxiety 2% 2% 3% 1% * Injection-site reaction is a composite term that includes injection-site abscess, bruising, discharge, discomfort, edema, erythema, hematoma, induration, infection, inflammation, injury, irritation, nodule, pain, pruritus, pustule, swelling, and ulcer. Dose Dependency of Adverse Reactions No dose dependency has been observed across WELTRUZA dose levels (corresponding to 10-20 mg/day oral olanzapine) for known olanzapine class effects. A dose group difference for oral olanzapine has been observed for fatigue, dizziness, weight gain and prolactin elevation. In a single 8-week randomized, double-blind, fixed-dose study comparing 10 (N=199), 20 (N=200) and 40 (N=200) mg/day of oral olanzapine in adult patients with schizophrenia or schizoaffective disorder, incidence of fatigue (10 mg/day: 1.5%; 20 mg/day: 2.1%; 40 mg/day: 6.6%) was observed with significant differences between 10 vs 40 and 20 vs 40 mg/day. The incidence of dizziness (10 mg/day: 2.6%; 20 mg/day: 1.6%; 40 mg/day: 6.6%) was observed with significant differences between 20 vs 40 mg. Dose group differences were also noted for weight gain and prolactin elevation for oral olanzapine [see Warnings and Precautions ( 5.5 , 5.15 )]. Injection Site Reactions During the 8-week double-blind, placebo-controlled period of the phase 3 trial, patients received two monthly injections of one of the WELTRUZA doses, or vehicle without active drug (placebo). Injection site reactions occurred in 29% of patients receiving WELTRUZA and in 8% of patients receiving placebo. Six patients (1.2%) who received WELTRUZA and none of the patients who received placebo were discontinued due to injection site reactions. The majority of injection site reactions were mild or moderate in severity and 0.7% of all injections resulted in a severe injection reaction. The most common injection site reactions (≥5% in any WELTRUZA group and higher than placebo) are presented in Table 6. Table 6: Injection Site Reactions: Incidence in a Short-Term, Placebo-Controlled Period of a Clinical Trial with WELTRUZA occurring in ≥5% in any WELTRUZA Group and Greater than Placebo Placebo (N=167) WELTRUZA 318mg (N=163) WELTRUZA 425mg (N=168) WELTRUZA 531mg (N=169) Total WELTRUZA (N=500) Patients with at least 1 injection site reaction* 8% 26% 29% 31% 29% Injection site induration 3% 11% 14% 14% 13% Injection site pain 4% 9% 11% 10% 10% Injection site erythema 1% 7% 13% 9% 10% Injection site pruritus 1% 6% 5% 7% 6% Injection site swelling 1% 6% 6% 4% 5% * Injection-site reaction is a composite term that includes injection-site abscess, bruising, discharge, discomfort, edema, erythema, hematoma, induration, infection, inflammation, injury, irritation, nodule, pain, pruritus, pustule, swelling, and ulcer. Less frequent ISRs (<5% and reported in at least 2 patients) reported throughout the phase 3 trial included: abscess, pustule, inflammation, irritation, edema, bruising, nodule, discharge, infection, and ulcer. Extrapyramidal Symptoms The following table enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by reported adverse reactions during the placebo controlled 8-week period of a clinical trial comparing three WELTRUZA doses with placebo in the treatment of schizophrenia. Table 7: Extrapyramidal Syndrome (SMQ): Incidence in a Short-Term, Placebo-Controlled Period of a Clinical Trial with WELTRUZA by Sub-SMQs, Preferred Term, and Treatment Group Placebo (N=167) WELTRUZA 318mg (N=163) WELTRUZA 425mg (N=168) WELTRUZA 531mg (N=169) Akathisia (SMQ) 1% 1% 1% 2% Akathisia 1% 1% 1% 2% Psychomotor hyperactivity 0% 0% 0% 1% Restlessness 0% 1% 0% 0% Dyskinesia (SMQ) 0% 1% 0% 1% Dyskinesia 0% 1% 0% 0% Muscle twitching 0% 0% 0% 1% Dystonia (SMQ) 1% 1% 0% 1% Dystonia 1% 1% 0% 1% Muscle spasms 0% 0% 0% 1% Preferred terms are sorted by descending order of incidence within sub-SMQ category for the Total WELTRUZA group. Patients are counted only once in each preferred term category, and only once in each sub-SMQ category. MedDRA=Medical Dictionary for Regulatory Activities; SMQ=standardized MedDRA query. Other Adverse Reactions Following is a list of treatment-emergent adverse reactions reported by patients treated with oral olanzapine (at multiple doses ≥1 mg/day) in clinical trials. This listing is not intended to include reactions (1) already listed in previous tables or elsewhere in labeling, (2) for which a drug cause was remote, (3) which were so general as to be uninformative, (4) which were not considered to have significant clinical implications, or (5) which occurred at a rate equal to or less than placebo. Reactions are classified by body system using the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; rare reactions are those occurring in fewer than 1/1000 patients. Body as a Whole — Infrequent: chills, face edema, photosensitivity reaction, suicide attempt; Rare: chills and fever, hangover effect, sudden death. Cardiovascular System — Infrequent: cerebrovascular accident, vasodilatation. Digestive System — Infrequent: abdominal distension, nausea and vomiting, tongue edema; Rare: ileus, intestinal obstruction, liver fatty deposit. Hemic and Lymphatic System — Infrequent: thrombocytopenia. Metabolic and Nutritional Disorders — Frequent: alkaline phosphatase increased; Infrequent: bilirubinemia, hypoproteinemia. Musculoskeletal System — Rare: osteoporosis. Nervous System — Infrequent: ataxia, dysarthria, libido decreased, stupor; Rare: coma. Respiratory System — Infrequent: epistaxis; Rare: lung edema. Skin and Appendages — Infrequent: alopecia. Special Senses — Infrequent: abnormality of accommodation, dry eyes; Rare: mydriasis. Urogenital System — Infrequent: amenorrhea, breast pain, decreased menstruation, impotence, increased menstruation, menorrhagia, metrorrhagia, polyuria, urinary frequency, urinary retention, urinary urgency, urination impaired. Vital Signs and Laboratory Studies Vital Sign Changes Oral olanzapine was associated with orthostatic hypotension and tachycardia in clinical trials. Intramuscular olanzapine for injection was associated with bradycardia, hypotension, and tachycardia in clinical trials [see Warnings and Precautions ( 5 )]. Laboratory Changes Olanzapine Monotherapy in Adults: An assessment of the premarketing experience for oral olanzapine revealed an association with asymptomatic increases in ALT, AST, and GGT. Within the original premarketing database of about 2400 adult patients with baseline ALT ≤90 IU/L, the incidence of ALT elevations to >200 IU/L was 2% (50/2381). None of these patients experienced jaundice or other symptoms attributable to liver impairment and most had transient changes that tended to normalize while olanzapine treatment was continued. In placebo-controlled oral olanzapine monotherapy studies in adults, clinically significant ALT elevations (change from <3 times the upper limit of normal [ULN] at baseline to ≥3 times ULN) were observed in 5% (77/1426) of patients exposed to olanzapine compared to 1% (10/1187) of patients exposed to placebo. ALT elevations ≥5 times ULN were observed in 2% (29/1438) of olanzapine-treated patients, compared to 0.3% (4/1196) of placebo-treated patients. ALT values returned to normal, or were decreasing, at last follow-up in the majority of patients who either continued treatment with olanzapine or discontinued olanzapine. No patient with elevated ALT values experienced jaundice, liver failure, or met the criteria for Hy’s Rule. From an analysis of the laboratory data in an integrated database of 41 completed clinical studies in adult patients treated with oral olanzapine, high GGT levels were recorded in ≥1% (88/5245) of patients. Caution should be exercised in patients with signs and symptoms of hepatic impairment, in patients with pre­-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic drugs. Oral olanzapine administration was also associated with increases in serum prolactin [see Warnings and Precautions ( 5.16 )] , with an asymptomatic elevation of the eosinophil count in 0.3% of patients, and with an increase in CPK. From an analysis of the laboratory data in an integrated database of 41 completed clinical studies in adult patients treated with oral olanzapine, elevated uric acid was recorded in ≥3% (171/4641) of patients. ECG Changes In pooled studies of adults as well as pooled studies of adolescents, there were no significant differences between oral olanzapine and placebo in the proportions of patients experiencing potentially important changes in ECG parameters, including QT, QTc (Fridericia corrected), and PR intervals. Oral olanzapine use was associated with a mean increase in heart rate compared to placebo in adults (+2.4 beats per minute vs no change with placebo). This increase in heart rate may be related to olanzapine’s potential for inducing orthostatic changes [see Warnings and Precautions ( 5.8 )] . 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of oral olanzapine. Because these reactions are reported voluntarily from a population of uncertain size, it is difficult to reliably estimate their frequency or evaluate a causal relationship to drug exposure. Adverse reactions reported since market introduction that were temporally (but not necessarily causally) related to oral olanzapine therapy and include the following: allergic reaction (e.g., anaphylactoid reaction, angioedema, pruritus or urticaria), cholestatic or mixed liver injury, diabetic coma, diabetic ketoacidosis, discontinuation reaction (diaphoresis, nausea or vomiting), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), hepatitis, jaundice, neutropenia, pancreatitis, priapism, rash, restless legs syndrome, rhabdomyolysis, salivary hypersecretion, stuttering, and venous thromboembolic events (including pulmonary embolism and deep venous thrombosis). Random cholesterol levels of ≥240 mg/dL and random triglyceride levels of ≥1000 mg/dL have been reported.

adverse reactions

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice. The safety of WELTRUZA for the treatment of schizophrenia in adults is based on adequate and well controlled studies of oral olanzapine in studies of patients with schizophrenia and other indications as well as in one 8-week placebo-controlled trial of WELTRUZA in adult patients with schizophrenia [see Clinical Studies ( 14 )]. The information below for WELTRUZA is derived primarily from a clinical trial database consisting of 849 patients receiving 3971 injections of WELTRUZA in 4 clinical trials. The majority of the safety data in this database is from a single phase 3 randomized, double-blind, placebo-controlled trial with an open-label, long-term safety phase conducted in patients with schizophrenia, with additional data from 3 open-label phase 1 trials, conducted in patients with schizophrenia or schizoaffective disorder. Additionally, data obtained from patients treated with oral olanzapine is also presented below. The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. Reactions listed elsewhere in labeling may not be repeated below. The entire label should be read to gain a complete understanding of the safety profile of WELTRUZA. The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects during usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing healthcare provider with some basis for estimating the relative contribution of drug and nondrug factors to the adverse reaction incidence in the population studied. Adverse Reactions Associated with Discontinuation of Trial in a Short-Term, Placebo-Controlled Period Overall, there was no meaningful difference in the incidence of discontinuation due to adverse reactions between WELTRUZA (5%; 23/500 patients) and placebo (4%; 6/167 patients) in an 8-week period. None of these Adverse Reactions occurred in >1% of patients. Commonly Observed Adverse Reactions in a Short-Term, Placebo-Controlled Trial The systemic safety profile of WELTRUZA was consistent with that of oral olanzapine. As such, injection site reactions (ISRs) are presented separately below, since they are specific to the injectable route of administration. In an 8-week placebo-controlled period, adverse reactions with an incidence of 5% or greater in at least one of the WELTRUZA treatment groups (318 mg, 425 mg, or 531 mg) and greater than placebo were: weight gain, injection site induration, injection site pain, injection site erythema, somnolence, headache, injection site pruritus, injection site swelling, and constipation. Adverse Reactions are presented in Table 5. Specific injection site reactions are presented in Table 6. Adverse Reactions Occurring at an Incidence of 2% or more among WELTRUZA-Treated Patients in a Short-Term, Placebo-Controlled Period of a Clinical Trial Table 5 enumerates the incidence, rounded to the nearest percent, of adverse reactions that occurred in 2% or more of patients treated with WELTRUZA and with incidence greater than placebo who participated in the 8-week, placebo-controlled period. Table 5: Adverse Reactions: Incidence in a Short-Term, Placebo-Controlled Period of a clinical trial occurring in ≥2% of patients in any WELTRUZA Group and Greater than Placebo Percentage of Patients Reporting Adverse Reaction Placebo (N=167) WELTRUZA 318mg (N=163) WELTRUZA 425mg (N=168) WELTRUZA 531mg (N=169) Investigations Weight increased 9% 30% 39% 34% Waist circumference increased 1% 1% 2% 3% Nervous System Disorders Somnolence 2% 10% 6% 8% Headache 7% 6% 8% 4% Gastrointestinal disorders Constipation 4% 2% 5% 5% Dry mouth 1% 2% 3% 4% Dyspepsia 1% 4% 2% 1% Toothache 0% 2% 1% 1% Nausea 2% 2% 1% 1% Metabolism and nutrition disorders Increased appetite 2% 4% 2% 2% Respiratory, thoracic and mediastinal disorders Cough 0% 1% 1% 3% General disorders and administration site conditions Injection site reaction* 8% 26% 29% 31% Fatigue 1% 2% 2% 1% Musculoskeletal and connective tissue disorders Schizophrenia 0% 2% 0% 2% Anxiety 2% 2% 3% 1% * Injection-site reaction is a composite term that includes injection-site abscess, bruising, discharge, discomfort, edema, erythema, hematoma, induration, infection, inflammation, injury, irritation, nodule, pain, pruritus, pustule, swelling, and ulcer. Dose Dependency of Adverse Reactions No dose dependency has been observed across WELTRUZA dose levels (corresponding to 10-20 mg/day oral olanzapine) for known olanzapine class effects. A dose group difference for oral olanzapine has been observed for fatigue, dizziness, weight gain and prolactin elevation. In a single 8-week randomized, double-blind, fixed-dose study comparing 10 (N=199), 20 (N=200) and 40 (N=200) mg/day of oral olanzapine in adult patients with schizophrenia or schizoaffective disorder, incidence of fatigue (10 mg/day: 1.5%; 20 mg/day: 2.1%; 40 mg/day: 6.6%) was observed with significant differences between 10 vs 40 and 20 vs 40 mg/day. The incidence of dizziness (10 mg/day: 2.6%; 20 mg/day: 1.6%; 40 mg/day: 6.6%) was observed with significant differences between 20 vs 40 mg. Dose group differences were also noted for weight gain and prolactin elevation for oral olanzapine [see Warnings and Precautions ( 5.5 , 5.15 )]. Injection Site Reactions During the 8-week double-blind, placebo-controlled period of the phase 3 trial, patients received two monthly injections of one of the WELTRUZA doses, or vehicle without active drug (placebo). Injection site reactions occurred in 29% of patients receiving WELTRUZA and in 8% of patients receiving placebo. Six patients (1.2%) who received WELTRUZA and none of the patients who received placebo were discontinued due to injection site reactions. The majority of injection site reactions were mild or moderate in severity and 0.7% of all injections resulted in a severe injection reaction. The most common injection site reactions (≥5% in any WELTRUZA group and higher than placebo) are presented in Table 6. Table 6: Injection Site Reactions: Incidence in a Short-Term, Placebo-Controlled Period of a Clinical Trial with WELTRUZA occurring in ≥5% in any WELTRUZA Group and Greater than Placebo Placebo (N=167) WELTRUZA 318mg (N=163) WELTRUZA 425mg (N=168) WELTRUZA 531mg (N=169) Total WELTRUZA (N=500) Patients with at least 1 injection site reaction* 8% 26% 29% 31% 29% Injection site induration 3% 11% 14% 14% 13% Injection site pain 4% 9% 11% 10% 10% Injection site erythema 1% 7% 13% 9% 10% Injection site pruritus 1% 6% 5% 7% 6% Injection site swelling 1% 6% 6% 4% 5% * Injection-site reaction is a composite term that includes injection-site abscess, bruising, discharge, discomfort, edema, erythema, hematoma, induration, infection, inflammation, injury, irritation, nodule, pain, pruritus, pustule, swelling, and ulcer. Less frequent ISRs (<5% and reported in at least 2 patients) reported throughout the phase 3 trial included: abscess, pustule, inflammation, irritation, edema, bruising, nodule, discharge, infection, and ulcer. Extrapyramidal Symptoms The following table enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by reported adverse reactions during the placebo controlled 8-week period of a clinical trial comparing three WELTRUZA doses with placebo in the treatment of schizophrenia. Table 7: Extrapyramidal Syndrome (SMQ): Incidence in a Short-Term, Placebo-Controlled Period of a Clinical Trial with WELTRUZA by Sub-SMQs, Preferred Term, and Treatment Group Placebo (N=167) WELTRUZA 318mg (N=163) WELTRUZA 425mg (N=168) WELTRUZA 531mg (N=169) Akathisia (SMQ) 1% 1% 1% 2% Akathisia 1% 1% 1% 2% Psychomotor hyperactivity 0% 0% 0% 1% Restlessness 0% 1% 0% 0% Dyskinesia (SMQ) 0% 1% 0% 1% Dyskinesia 0% 1% 0% 0% Muscle twitching 0% 0% 0% 1% Dystonia (SMQ) 1% 1% 0% 1% Dystonia 1% 1% 0% 1% Muscle spasms 0% 0% 0% 1% Preferred terms are sorted by descending order of incidence within sub-SMQ category for the Total WELTRUZA group. Patients are counted only once in each preferred term category, and only once in each sub-SMQ category. MedDRA=Medical Dictionary for Regulatory Activities; SMQ=standardized MedDRA query. Other Adverse Reactions Following is a list of treatment-emergent adverse reactions reported by patients treated with oral olanzapine (at multiple doses ≥1 mg/day) in clinical trials. This listing is not intended to include reactions (1) already listed in previous tables or elsewhere in labeling, (2) for which a drug cause was remote, (3) which were so general as to be uninformative, (4) which were not considered to have significant clinical implications, or (5) which occurred at a rate equal to or less than placebo. Reactions are classified by body system using the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; rare reactions are those occurring in fewer than 1/1000 patients. Body as a Whole — Infrequent: chills, face edema, photosensitivity reaction, suicide attempt; Rare: chills and fever, hangover effect, sudden death. Cardiovascular System — Infrequent: cerebrovascular accident, vasodilatation. Digestive System — Infrequent: abdominal distension, nausea and vomiting, tongue edema; Rare: ileus, intestinal obstruction, liver fatty deposit. Hemic and Lymphatic System — Infrequent: thrombocytopenia. Metabolic and Nutritional Disorders — Frequent: alkaline phosphatase increased; Infrequent: bilirubinemia, hypoproteinemia. Musculoskeletal System — Rare: osteoporosis. Nervous System — Infrequent: ataxia, dysarthria, libido decreased, stupor; Rare: coma. Respiratory System — Infrequent: epistaxis; Rare: lung edema. Skin and Appendages — Infrequent: alopecia. Special Senses — Infrequent: abnormality of accommodation, dry eyes; Rare: mydriasis. Urogenital System — Infrequent: amenorrhea, breast pain, decreased menstruation, impotence, increased menstruation, menorrhagia, metrorrhagia, polyuria, urinary frequency, urinary retention, urinary urgency, urination impaired. Vital Signs and Laboratory Studies Vital Sign Changes Oral olanzapine was associated with orthostatic hypotension and tachycardia in clinical trials. Intramuscular olanzapine for injection was associated with bradycardia, hypotension, and tachycardia in clinical trials [see Warnings and Precautions ( 5 )]. Laboratory Changes Olanzapine Monotherapy in Adults: An assessment of the premarketing experience for oral olanzapine revealed an association with asymptomatic increases in ALT, AST, and GGT. Within the original premarketing database of about 2400 adult patients with baseline ALT ≤90 IU/L, the incidence of ALT elevations to >200 IU/L was 2% (50/2381). None of these patients experienced jaundice or other symptoms attributable to liver impairment and most had transient changes that tended to normalize while olanzapine treatment was continued. In placebo-controlled oral olanzapine monotherapy studies in adults, clinically significant ALT elevations (change from <3 times the upper limit of normal [ULN] at baseline to ≥3 times ULN) were observed in 5% (77/1426) of patients exposed to olanzapine compared to 1% (10/1187) of patients exposed to placebo. ALT elevations ≥5 times ULN were observed in 2% (29/1438) of olanzapine-treated patients, compared to 0.3% (4/1196) of placebo-treated patients. ALT values returned to normal, or were decreasing, at last follow-up in the majority of patients who either continued treatment with olanzapine or discontinued olanzapine. No patient with elevated ALT values experienced jaundice, liver failure, or met the criteria for Hy’s Rule. From an analysis of the laboratory data in an integrated database of 41 completed clinical studies in adult patients treated with oral olanzapine, high GGT levels were recorded in ≥1% (88/5245) of patients. Caution should be exercised in patients with signs and symptoms of hepatic impairment, in patients with pre­-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic drugs. Oral olanzapine administration was also associated with increases in serum prolactin [see Warnings and Precautions ( 5.16 )] , with an asymptomatic elevation of the eosinophil count in 0.3% of patients, and with an increase in CPK. From an analysis of the laboratory data in an integrated database of 41 completed clinical studies in adult patients treated with oral olanzapine, elevated uric acid was recorded in ≥3% (171/4641) of patients. ECG Changes In pooled studies of adults as well as pooled studies of adolescents, there were no significant differences between oral olanzapine and placebo in the proportions of patients experiencing potentially important changes in ECG parameters, including QT, QTc (Fridericia corrected), and PR intervals. Oral olanzapine use was associated with a mean increase in heart rate compared to placebo in adults (+2.4 beats per minute vs no change with placebo). This increase in heart rate may be related to olanzapine’s potential for inducing orthostatic changes [see Warnings and Precautions ( 5.8 )] .

adverse reactions

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of oral olanzapine. Because these reactions are reported voluntarily from a population of uncertain size, it is difficult to reliably estimate their frequency or evaluate a causal relationship to drug exposure. Adverse reactions reported since market introduction that were temporally (but not necessarily causally) related to oral olanzapine therapy and include the following: allergic reaction (e.g., anaphylactoid reaction, angioedema, pruritus or urticaria), cholestatic or mixed liver injury, diabetic coma, diabetic ketoacidosis, discontinuation reaction (diaphoresis, nausea or vomiting), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), hepatitis, jaundice, neutropenia, pancreatitis, priapism, rash, restless legs syndrome, rhabdomyolysis, salivary hypersecretion, stuttering, and venous thromboembolic events (including pulmonary embolism and deep venous thrombosis). Random cholesterol levels of ≥240 mg/dL and random triglyceride levels of ≥1000 mg/dL have been reported.

adverse reactions table

<table width="800px" cellspacing="0" cellpadding="5"> <caption>Table 5: Adverse Reactions: Incidence in a Short-Term, Placebo-Controlled Period of a clinical trial occurring in &#x2265;2% of patients in any WELTRUZA Group and Greater than Placebo </caption> <col width="211.9pt"/> <col width="255.3pt"/> <col/> <col/> <col/> <tbody> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/> <td align="center" colspan="4" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Percentage of Patients Reporting Adverse Reaction</content> </paragraph> </td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Placebo </content> <content styleCode="bold">(N=167)</content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">WELTRUZA 318mg </content> <content styleCode="bold">(N=163)</content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">WELTRUZA 425mg </content> <content styleCode="bold">(N=168)</content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">WELTRUZA 531mg </content> <content styleCode="bold">(N=169)</content> </paragraph> </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Investigations</content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Weight increased</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>9%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>30%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>39%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>34%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Waist circumference increased</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>3%</paragraph> </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Nervous System Disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Somnolence</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>10%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>6%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>8%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Headache</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>7%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>6%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>8%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4%</paragraph> </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Gastrointestinal disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Constipation</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>5%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>5%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Dry mouth</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>3%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Dyspepsia</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Toothache</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>0%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Nausea</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Metabolism and nutrition disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Increased appetite</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Cough</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>0%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>3%</paragraph> </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">General disorders and administration site conditions</content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Injection site reaction* </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>8%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>26%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>29%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>31%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Fatigue</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Musculoskeletal and connective tissue disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Schizophrenia</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>0%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>0%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Anxiety</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>3%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> </tr> <tr> <td colspan="5"> <content styleCode="italics">*</content> Injection-site reaction is a composite term that includes injection-site abscess, bruising, discharge, discomfort, edema, erythema, hematoma, induration, infection, inflammation, injury, irritation, nodule, pain, pruritus, pustule, swelling, and ulcer.</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.